Search Results 81-90 of 16677 for ������������KA���:ZA31���24������ ���������������������������������

  1. Clinical trials - Oncology (Medical)

    The percentage of subjects who can enroll on an A2 CAR T-cell therapy study within approximately 24 months of HLA-A LOH status; Percentage of screened ...

  2. Belzutifan with Von Hippel-Lindau (VHL) - Mayo Clinic

    Rochester, Minnesota: 24-007537; Scottsdale/Phoenix, Arizona: 24-007537. Sponsor Protocol Number: 6482-026. About this study. The purpose of this study is to ...

  3. Clinical Trials - 2024 Archives

    October 24, 2024. The dynamic role of clinical research coordinators. Caitlin Doran. October 17, 2024. Mayo Clinic, Carnegie Mellon researchers secure ARPA-H ...

  4. Publications - Max A. Hawkes, M.D. - Mayo Clinic

    2018 Jan; 8 (1):24-28 Epub 2017 Sept 27. View PubMed; Hawkes MA, Wilken M, Vazquez G, Farez MF. Age may contribute to the increased frequency of axonal ...

  5. Breast cancer - Doctors and departments - Mayo Clinic

    Has anyone taken Lynparza? 24 Replies Sat, Jun 07, 2025. See more discussions. Related. Breast cancer chemoprevention · Breast Cancer Education Tool · Breast ...

  6. Publications - Dimitar K. Gavrilov, M.D., Ph.D. - Mayo Clinic

    Epub 2024 Mar 24. View PubMed; Hall PL, Liedke K ... KA, Peterson C, Pettersen RD, Pitt JJ, Poh S ... 1991; (24):219. View PubMed; Gavrilov DK ...

  7. Publications - Nirvi Dahiya, M.D. - Mayo Clinic

    Comparative sensitivity and accuracy of 24 vs. ... KA, Menias CO. Spectrum of imaging findings in ... 2017 Nov - Dec; 24 (7):1170-1176 Epub 2017 July 08

  8. Breast cancer - Doctors and departments - Mayo Clinic

    Analyzing the genetic makeup of breast cancer cells to understand how DNA changes affect response to cancer treatments and personalize treatment options.

  9. Publications

    2001 Jan; 24(1):60-3. ... Pranzatelli MR, Hanin I, Tate E, Kindel G, Bergin A, Brown CM, Habersang P, Habersang R, Mack KJ, Rosenbaum B, Selby KA, Vasconcellos M.

  10. Efficacy and Safety of Seralutinib in Adult Subjects With PAH - Mayo Clinic

    Subjects receiving treatment with sotatercept are eligible only if on a stable dose of sotatercept for at least 24 weeks prior to and throughout Screening ...